Tine Wyseure

Tine Wyseure has a strong background in scientific research and pharmaceuticals. Tine is currently employed at Vividion Therapeutics, Inc. as a Principal Scientist, a role they have held since January 2023. Prior to that, they worked at the same company as a Senior Scientist from February 2022 to January 2023, as a Scientist II from January 2021 to February 2022, and as a Scientist I from November 2019 to January 2021.

Before joining Vividion Therapeutics, Tine Wyseure worked at The Scripps Research Institute as a Postdoctoral fellow from January 2015 to November 2019. Their main project involved exploring the mechanisms of pathological vascular remodeling in hemophilic joint disease to develop new therapies for joint healing in hemophilia patients. Tine optimized 3D imaging modalities for evaluating treatments after joint bleeding.

Prior to their postdoctoral fellowship, Tine Wyseure worked at KU Leuven as a PhD student from October 2009 to September 2014. Their research focused on evaluating the dual inhibition of TAFI and PAI-1 and generating bispecific antibody candidates against stroke risk factors. This research led to a patented invention for a safe and effective thrombolytic strategy.

Tine Wyseure also gained experience as a Scientific Collaborator at INSERM for a brief period in 2013 and worked briefly as a Pharmacist at Apoteek Maleizen Centrum in 2009.

Tine began their research career as an Undergraduate Research Student at the Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal, where they worked on clarifying the sorting mechanisms of newly synthesized Peroxisomal membrane proteins (PMPs) and completed their master's thesis on Pex19p-(GFP-)PMP24 interaction.

In summary, Tine Wyseure has a diverse range of experience in scientific research and pharmaceuticals, with a focus on vascular remodeling, therapeutic efficacy, and thrombolytic strategies.

Tine Wyseure obtained a Master's degree in Pharmaceutical Sciences from KU Leuven in 2009. Tine later pursued a PhD in Pharmaceutical Sciences with a focus on Antibody Engineering & Thrombosis and Hemostasis at the same institution, completing it in 2014.